Literature DB >> 26977783

Immunotherapy: PD-1 says goodbye, TIM-3 says hello.

Diana Romero.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26977783     DOI： 10.1038/nrclinonc.2016.40

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

Authors:  Shohei Koyama; Esra A Akbay; Yvonne Y Li; Grit S Herter-Sprie; Kevin A Buczkowski; William G Richards; Leena Gandhi; Amanda J Redig; Scott J Rodig; Hajime Asahina; Robert E Jones; Meghana M Kulkarni; Mari Kuraguchi; Sangeetha Palakurthi; Peter E Fecci; Bruce E Johnson; Pasi A Janne; Jeffrey A Engelman; Sidharta P Gangadharan; Daniel B Costa; Gordon J Freeman; Raphael Bueno; F Stephen Hodi; Glenn Dranoff; Kwok-Kin Wong; Peter S Hammerman
Journal:  Nat Commun       Date:  2016-02-17       Impact factor: 14.919
  1 in total
  25 in total

1.  Osteopontin controls immunosuppression in the tumor microenvironment.

Authors:  Michael R Shurin
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

2.  Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.

Authors:  Guanzhang Li; Zheng Wang; Chuanbao Zhang; Xing Liu; Jinquan Cai; Zhiliang Wang; Huimin Hu; Fan Wu; Zhaoshi Bao; Yanwei Liu; Liang Zhao; Tingyu Liang; Fan Yang; Ruoyu Huang; Wei Zhang; Tao Jiang
Journal:  Oncoimmunology       Date:  2017-07-28       Impact factor: 8.110

3.  Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles.

Authors:  Chenghua Song; Jia Zhang; Ruichao Wen; Qingshan Li; Jiaxuan Zhou; Zheng Wu; Yi Lv; Rongqian Wu
Journal:  Mater Today Bio       Date:  2022-07-06

4.  Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.

Authors:  Yi Luo; Yi-Chen Yang; Cen-Kai Shen; Ben Ma; Wei-Bo Xu; Qi-Feng Wang; Yan Zhang; Tian Liao; Wen-Jun Wei; Yu Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-27       Impact factor: 6.055

5.  NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.

Authors:  Qingqing Cai; Meifeng Tu; Zijun Y Xu-Monette; Ruifang Sun; Ganiraju C Manyam; Xiaolu Xu; Alexander Tzankov; Eric D Hsi; Michael B Møller; L Jeffrey Medeiros; Chi Young Ok; Ken H Young
Journal:  Mod Pathol       Date:  2017-03-10       Impact factor: 7.842

Review 6.  Recent Advances in Immunotherapy in Metastatic NSCLC.

Authors:  Pranshu Bansal; Diaa Osman; Gregory N Gan; George R Simon; Yanis Boumber
Journal:  Front Oncol       Date:  2016-11-14       Impact factor: 6.244

7.  Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.

Authors:  Zheng Wang; Chuanbao Zhang; Xing Liu; Zhiliang Wang; Lihua Sun; Guanzhang Li; Jingshan Liang; Huimin Hu; Yanwei Liu; Wei Zhang; Tao Jiang
Journal:  Oncoimmunology       Date:  2016-06-16       Impact factor: 8.110

8.  Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma.

Authors:  Zhu Li; Na Li; Fang Li; Zhihua Zhou; Jiao Sang; Yanping Chen; Qunying Han; Yi Lv; Zhengwen Liu
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

9.  The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9/Tim-3-related changes in the tumour microenvironment.

Authors:  Tseng-Cheng Chen; Chao-Hsien Chen; Cheng-Ping Wang; Pei-Hsuan Lin; Tsung-Lin Yang; Pei-Jen Lou; Jenq-Yuh Ko; Chen-Tu Wu; Yih-Leong Chang
Journal:  Sci Rep       Date:  2017-09-04       Impact factor: 4.379

Review 10.  Role of Galectins in Tumors and in Clinical Immunotherapy.

Authors:  Feng-Cheng Chou; Heng-Yi Chen; Chih-Chi Kuo; Huey-Kang Sytwu
Journal:  Int J Mol Sci       Date:  2018-02-01       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.